Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $25.71 Consensus PT from Brokerages

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been assigned a consensus rating of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.71.

A number of analysts have recently issued reports on KYTX shares. HC Wainwright lowered their price objective on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. Wells Fargo & Company lowered their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, November 15th.

Kyverna Therapeutics Stock Down 2.7 %

Shares of NASDAQ KYTX opened at $2.89 on Thursday. Kyverna Therapeutics has a 12 month low of $2.64 and a 12 month high of $30.60. The business’s 50 day moving average is $3.53 and its two-hundred day moving average is $5.05.

Institutional Trading of Kyverna Therapeutics

Institutional investors have recently bought and sold shares of the stock. FMR LLC acquired a new stake in Kyverna Therapeutics in the 3rd quarter valued at $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at $34,000. Squarepoint Ops LLC acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at $43,000. Corton Capital Inc. acquired a new position in Kyverna Therapeutics in the fourth quarter worth $45,000. Finally, Corebridge Financial Inc. boosted its stake in Kyverna Therapeutics by 42.3% in the fourth quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock worth $48,000 after purchasing an additional 3,810 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.